Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY)
Yahoo Financearrow_outwardLilly confirms date and conference call for second-quarter 2025 financial results announcement
RochesterFirstarrow_outwardEli Lilly and Company (NYSE:LLY) Stock Rating Upgraded by Wall Street Zen
MarketBeatarrow_outward(LLY) Investment Analysis and Advice - news.stocktradersdaily.com
News.stocktradersdaily.comarrow_outwardAnalyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY) - Insider Monkey
Insider Monkeyarrow_outwardMorgan Stanley Remains Bullish on Eli Lilly (LLY) - sg.finance.yahoo.com
Sg.finance.yahoo.comarrow_outwardEli Lilly (LLY) Completes Acquisition of Verve Therapeutics | LL - GuruFocus
GuruFocusarrow_outwardLilly Acquires Verve Therapeutics, Targets One-Time Cardiovascular Treatment | LLY Stock News - Stock Titan
Stock Titanarrow_outwardFund Update: Blue Trust, Inc. added 39,094 shares of ELI LILLY ($LLY) to their portfolio - Quiver Quantitative
Quiver Quantitativearrow_outwardEli Lilly (LLY) Collaborates With Gate Bioscience For Innovative Molecular Gate Therapeutics - simplywall.st
Simplywall.starrow_outwardThe 3 Things That Matter for Eli Lilly Now - The Motley Fool
The Motley Foolarrow_outwardBMO Capital Pounds the Table on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks
TipRanksarrow_outwardWhy Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Nasdaq
Nasdaqarrow_outwardEli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha
Seeking Alphaarrow_outwardEli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025) - 24/7 Wall St.
24/7 Wall St.arrow_outwardEli Lilly and Company (LLY) Stock: US FDA Approves Safer Kisunla Dosing for Early Alzheimer’s - CoinCentral
CoinCentralarrow_outwardUBS Reiterates Buy Rating on Eli Lilly Stock (LLY) as Weight-Loss Drug Sales Accelerate - MSN
MSNarrow_outwardEli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell A Different Story - Barchart.com
Barchart.comarrow_outwardLLY Stock Too Cheap At $750? - Forbes
Forbesarrow_outwardLLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study - Zacks Investment Research
Zacks Investment Researcharrow_outward
Lly Stock close
- 2025-07-29 19:30 event
- 20 sourceslanguage
- 100+ ads_click
- 1 week ago schedule